CASI חוב כולל להון CASI Pharmaceuticals

CASI Pharmaceuticals (CASI) focuses on the Chinese oncology market, increasing Evomela sales and developing the promising CID-103 through Asian alliances. However, profitability is constrained by strict government procurement regulations that force sharp price reductions. This chart of the current share price demonstrates a debt-to-equity ratio of 0.00, highlighting the financial stability of a licensing model for Western drugs that minimizes primary research costs.

This ratio measures the proportion of borrowed funds relative to equity, allowing a conservative investor to assess the business's dependence on creditors through the dynamics of the company's financial leverage. The low debt load of CASI Pharmaceuticals (CASI) confirms the resilience of its strategy to license Western drugs and organically develop its pipeline in China without relying on risky M&A transactions, ensuring the issuer's long-term solvency.